"Insider buying is one of the few market signals that does not hide behind algorithms or price targets. When a director pulls out a personal checkbook and adds to his stake while the rest of the Street is bickering about next quarter's guidance, he is speaking in the clearest language available. 2025 is shaping up to be a year when insiders are putting their money to work with unusual speed."
"LLY stock has declined 15.61% in the past year, and management is taking the opportunity to load up. Eli Lilly has been on a record winning streak, and this is the first time since 2008 that the stock has noticeably declined to such an extent. Insiders, however, don't seem to think this will last long.... and I'd have to agree."
Insider buying is presented as a clear market signal when directors purchase shares personally rather than relying on algorithms or price targets. Insiders accelerated open-market purchases in 2025 across several companies, with Eli Lilly and Matador Resources notable for recent activity. Eli Lilly stock fell 15.61% over the past year while revenue grew 37.64% year-over-year to $15.56 billion in Q2 and net income rose 90.78% to $5.66 billion. Analysts forecast substantial EPS and revenue growth for 2025–2026. Novartis underperformed, down 56.7% year-over-year. Matador Resources produces and sells U.S. oil and gas and has increased dividends consistently.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]